Boston Scientific Tries To Climb Back Up From ICD Market Share Spill

Boston Scientific is banking on intense communication with physicians and new product launches to eventually pull its ICD business back to its pre-sales-suspension standing, but the firm acknowledges that it will be playing catch-up for the foreseeable future